| Size | Price | Stock | Qty |
|---|---|---|---|
| Other Sizes |
|
| ln Vitro |
Coenzyme Q0 (0–40 μM; 24 h) prevents the growth and viability of human ovaries [1]. Coenzyme Q0 (CoQ0) (0-30 μM; 24 h; SKOV-3 cells) inhibits cell division by lowering cell cycle regulatory proteins and inducing G2/M cell cycle induction [1]. Coenzyme Q0 (CoQ0) (0-30 μM; 0-30 minutes; SKOV-3 cells) raises intracellular ROS levels to encourage the death of SKOV-3 cells [1]; via increasing the accumulation of LC3-II, GFP-LC3 pigment, AVO formation, and Beclin-1/Bcl-2 repair, Coenzyme Q0 (CoQ0) (0-30 μM; 24 hours; SKOV-3 cells) induces self-repair. Coenzyme Q0 (CoQ0) (0-30 μM; 24 hours; SKOV-3 cells) inhibits HER-2/AKT/mTOR signaling to improve cytochrome and autophagy mechanisms. Coenzyme Q0 (CoQ0) signals through mitochondria (caspase-3, PARP, and Bax/Bcl-2 corrector) and ER intermediates (caspase-12 and Hsp70) [1]. Q0 (CoQ0) (0-10 μM; 0.5-18 hours; RAW264.7 cells) improves Nrf2 stability and controls NFκB/AP-1 activation [2]. 5 μM Coenzyme Q0 (CoQ0); 0–12 hours;
|
|---|---|
| ln Vivo |
In SKOV-3 xenografted nude mice, intraperitoneal administration of Coenzyme Q0 (CoQ0) at 1.5 and 2.5 mg/kg every four days for 52 days inhibits the growth of tumors [1]. Through Nrf2 activation and NFκB inhibition, Coenzyme Q0 (CoQ0) (5 mg/kg; lateral wall; duration: 4 hours) has anti-inflammatory activity in the liver and the liver of mice treated with lipopolysaccharide (LPS) [2].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: SKOV-3, A2780 and A2870/CP70 cells Tested Concentrations: 0, 10, 20, 30 EA.hy 926 cells) in EA Anti-angiogenic activity in .hy 926 cells [3]. and 40 µM Incubation Duration: 24 hrs (hours) Experimental Results: The viability of SKOV-3, A2780 and A2870/CP70 cells was diminished, with IC50 values of 26.6 µM, 27.3 µM and 28.4 µM respectively. Cell cycle analysis[1] Cell Types: SKOV-3, A2780 and A2870/CP70 Cell Tested Concentrations: 0, 10, 20 and 30 µM Incubation Duration: 24 hrs (hours) Experimental Results: Cell cycle arrest in G2/M phase and diminished cyclin expression in in SKOV-3 cells. Apoptosis analysis[1] Cell Types: SKOV-3, A2780 and A2870/CP70 Cell Tested Concentrations: 0, 5, 15 and 30 µM Incubation Duration: 24 hrs (hours) Experimental Results: Promoted conversion of LC3–1 to LC3-II and increased LC3 -II accumulation. The Bax/Bcl-2 ratio increased in a dose-dependent manner. Apoptosis analysis[1] Cell Types: SKOV-3 Cell Tested Concentrations: 0, 10, 20 and 30 µM Incubation Duration: 24 hrs (hours) Experimental Results: Had the percentage of early apoptotic cells are 25.1%, 34% and 36% for 10, 20 and 30 µM, respectively. Western Blot Analysis[1] Cell Types: SKOV-3 cells Tested Concentrations: 0, 5, 15 and 30 µM Incubation Duration: 24 hrs (hours) Experimental Results: Activated of caspase-3 and cleavaged of PARP. Increased the expressions of caspase-12, HSP-70 and Bax in a dose-dependent manner, diminished the expressions of Bcl-2. Western Blot Analysis[1] Cell Types: SKOV-3 cells Tested Concentrations: 30 µM Incubation Duration: 24 hrs (hours) Experimental Results: diminished the phosphorylated HER-2 (Y1221) levels, p-AKT (Ser473) and p-mTOR (S2448) levels. Western Blot Analysis[2] Cell Types: RAW264.7 cells Tested Concentrations: 0, 2.5, 5 and 10 µM Incubation Duration: 0.5-18 hrs (hours) Experimental Results: Inhibited iNOS/COX-2 protein expressions with reductions of NO, PGE2, TNF-α and IL-1β secretions. Western Blot Analysis[3] Cell Types: EA.hy 926 cells Tested Concentrations: 5 µM Incubation Duration: 0, 1, 3, 6 and 12 hrs (hours) Experimental Results: Increased expressions of heme oxygenase-1 (HO-1) and γ-glutamylcysteine synthetase (γ-GCLC), inhibits protein expressions of matrix metalloproteinase-9 (MMP-9), reduces TNF-α-induced nuclear translocation and transcriptional activation of nuclear factor-κB (NF-κB). |
| Animal Protocol |
Animal/Disease Models: SKOV-3 xenograft nude mice [1]
Doses: 1.5 and 2.5 mg/kg Route of Administration: intraperitoneal (ip) injection; once every four days for 52 days Experimental Results: 1.5 and 2.5 mg/kg inhibited tumor growth. Animal/Disease Models: LPS-treated female FVB mice [2] Doses: 5 mg/kg Route of Administration: po (po (oral gavage)) 4 hrs (hrs (hours)) Experimental Results: Down-regulated inflammatory genes in the liver and spleen tissues of LPS-injected mice. |
| References |
|
| Additional Infomation |
Ubiquinone-0 is a derivative of benzoquinone carrying a 5-methyl substituent; and methoxy substituents at positions 2 and 3. The core structure of the ubiquinone group of compounds. It has a role as an Escherichia coli metabolite and a human metabolite.
Ubiquinone-0 is a metabolite found in or produced by Escherichia coli (strain K12, MG1655). 2,3-Dimethoxy-5-methyl-1,4-benzoquinone has been reported in Antrodia cinnamomea, Taiwanofungus salmoneus, and Taiwanofungus camphoratus with data available. |
| Molecular Formula |
C9H10O4
|
|---|---|
| Molecular Weight |
182.1733
|
| Exact Mass |
182.057
|
| CAS # |
605-94-7
|
| PubChem CID |
69068
|
| Appearance |
Brown to red solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
331.4±42.0 °C at 760 mmHg
|
| Melting Point |
58-60 °C(lit.)
|
| Flash Point |
148.6±27.9 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.498
|
| LogP |
0.12
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
13
|
| Complexity |
323
|
| Defined Atom Stereocenter Count |
0
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~274.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (9.17 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (9.17 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4894 mL | 27.4469 mL | 54.8938 mL | |
| 5 mM | 1.0979 mL | 5.4894 mL | 10.9788 mL | |
| 10 mM | 0.5489 mL | 2.7447 mL | 5.4894 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
